Macular edema is defined as an accumulation of fluid in the outer plexiform layer and the inner nuclear layer as well as a swelling of Müller cells of the retina. It consists of a localized expansion of the retinal extracellular space (sometimes associated with the intracellular space) in the macular area. Macular edema is a common cause of a sudden or chronic decrease in visual acuity occurring in many ocular diseases such as age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. As a nonspecific sign of many intraocular and systemic diseases, macular edema represents a common final pathway. The existence of the blood-retinal barrier (BRB) formed by intercellular junctions is the precondition required to maintain this physiological status. This status may become severely disturbed by many diseases, finally resulting in macular edema. In this article, the development of macular edema will also be classified by its pathophysiological and pathobiochemical pathways. Vascular components, the dysfunctional BRB, the role of proteins and water fluxes as well as the role of several inflammatory mediators (e.g. angiotensin II, vascular endothelial growth factor, prostaglandins) in the retina will be discussed as responsible mechanisms leading to the development of macular edema.

Keywords:
Macular edema, Pathophysiology, Blood-retinal barrier, Vascular endothelial growth factor
1.
Marmor MF: Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999;97:239–249.
2.
Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE: Macular edema. Surv Ophthalmol 2004;49:470–490.
3.
Rotsos TG, Moschos MM: Cystoid macular edema. Clin Ophthalmol 2008;2:919–930.
4.
Finkelstein D: Ischemic macular edema: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992;110:1427–1434.
5.
Joussen AM, Smyth N, Niessen C: Pathophysiology of diabetic macular edema. Dev Ophthalmol 2007;39:1–12.
6.
Pasqualetti G, Danesi R, del Tacca M, Bocci G: Vascular endothelial growth factor pharmacogenetics: a new perspective for anti-angiogenic therapy. Pharmacogenomics 2007;8:49–66.
7.
Kersten AJ, Althaus C, Best J, Sundmacher R: Cystoid macular edema following immune recovery and treatment with cidofovir for cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol 1999;237:893–896.
8.
Funatsu H, Yamashita H: Pathogenesis of diabetic retinopathy and the renin-angiotensin system. Ophthalmic Physiol Opt 2003;23:495–501.
9.
Cheng ZJ, Vapaatalo H, Mervaala E: Angiotensin II and vascular inflammation. Med Sci Monit 2005;11:194–205.
10.
Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–442.
11.
Ishida S, Usui T, Yamashiro K, Kaji Y, Ahmed E, Carrasquillo KG, Amano S, Hida T, Oguchi Y, Adamis AP: VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:2155–2162.
12.
Pannicke T, Iandiev I, Uckermann O, Biedermann B, Kutzera F, Wiedemann P, Wolburg H, Reichenbach A, Bringmann A: A potassium channel-linked mechanism of glial cell swelling in the postischemic retina. Mol Cell Neurosci 2004;26:493–502.
13.
Girach A, Lund-Andersen H: Diabetic macular edema: a clinical overview. Int J Clin Pract 2007;61:88–97.
14.
Klein R, Knudtson MD, Lee KE, Gangnon R, Klein BE: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497–503.
15.
Rodriguez-Fontal M, Kerrison JB, Alfaro DV, Jablon EP: Metabolic control and diabetic retinopathy. Curr Diabetes Rev 2009;5:3–7.
16.
Ikeda T: The pathogenesis of vitreoretinal diseases from the standpoint of molecular biology. Nippon Ganka Gakkai Zasshi 2003;107:785–812.
17.
Morales S, Garcia-Salcedo JA, Munoz-Torres M: Pentosidine: a new biomarker in diabetes mellitus complications (in Spanish). Med Clin (Barc) 2010, E-pub ahead of print.
18.
Gulkilik G, Kocabora S, Taskapili M, Engin G: Cystoid macular edema after phacoemulsification: risk factors and effect on visual acuity. Can J Ophthalmol 2006;41:699–703.
19.
Guex-Crosier Y: The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol 1999;97:297–309.
20.
Yeh S, Li Z, Forooghian F, Hwang FS, Cunningham MA, Pantanelli S, Lew JC, Wroblewski KK, Vitale S, Nussenblatt RB: CD4+Foxp3+ T-regulatory cells in noninfectious uveitis. Arch Ophthalmol 2009;127:407–413.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.